D3 Pharma & Encap Drug Delivery Continue Partnership
D3 Pharma Limited recently announced its continuing partnership with Encap Drug Delivery to expedite the commercial manufacturing and product licensing program for its proprietary high-dose oral vitamin D3 product, Plenachol, for the treatment of vitamin D deficiency and insufficiency. Plenachol is a patented liquid-filled capsule formulation of vitamin D3, which was developed in conjunction with Encap and is available at three dose-strengths: 20,000, 40,000, and 100,000 international units.
Plenachol has a unique formulation base, which is free from animal-derived excipients and peanut constituents. The utility of Encap’s world-class capsule liquid-filling technology secures Plenachol as a first and best-in-class high-dose oral vitamin D3 product. Plenachol will continue to be made available as a Specials product during the pre-license phase via Encap Drug Delivery. For more information regarding Plenachol Specials supply please contact: Dr. Janice McLachlan (JMcLachlan@encap
D3 Pharma is a privately owned specialty pharmaceutical company based in the
Encap Drug Delivery is the world’s largest contract development and manufacturing organization (CDMO) totally dedicated to liquid and semi-solid (hot melt) filled capsules. The company was established in 1989 and is a global provider of oral drug delivery and pharmaceutical development services. The company provides clients with fully integrated analytical and formulation development services, clinical trial manufacturing, and high-volume commercial manufacturing. Encap’s state-of-the-art facility in the
Total Page Views: 1523
